antiplatelet drugs, adenosine diphosphate (ADP) receptor inhibitors, clopidogrel (75 mg/d)
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2005 Nov 5;366(9497):1607-21 Randomized Controlled Trial, Multicenter Study
IN coronary disease, myocardial infarction, ST-segment elevation The Use of
antiplatelet drugs, adenosine diphosphate (ADP) receptor inhibitors, clopidogrel (75 mg/d) added to standard Tt (aspirin 100%, fibrinolysis 50%, anticoagulant 75%)
As Treatment, Acute
Is better Than
aspirin alone and standard antithrombotic Tt
To To reduce at 30 days vascular events (death, recurrent infarction, stroke): 9,2% with clopidogrel VS 10,1% aspirin alone.
N Engl J Med. 2012 Aug 30;367(9):817-25 Randomized Controlled Trial, Multicenter Study
IN stroke, ischemic, lacunar, recent The Use of
combined antiplatelet drugs, adenosine diphosphate (ADP) receptor inhibitors, clopidogrel (75 mg/d) added to aspirin (325 mg/d)
As Treatment, Chronic
Is equal Than
aspirin alone
To modify the the risk of recurrent stroke: 2.5% per year dual therapy VS 2.7% per year aspirin alone
Stroke. 2012 Apr;43(4):1058-66. Epub 2012 Jan 26 Meta-Analysis
IN stroke, ischemic, thrombotic, transient ischemic attack The Use of
combined antiplatelet drugs, adenosine diphosphate (ADP) receptor inhibitors, clopidogrel (75 mg/d) plus low-dose aspirin
As Prevention, Secondary
Is equal Than
aspirin alone
To reduce stroke recurrence (aspirin+clopidogrel VS aspirin alone : RR 0.67, 95%CI 0.37-1.23). However, a strong trend to reduce combined major cardiovascular events or death (OR 0.68, 95%CI 0.45-1.03, p=0.07).